Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.51 |
| ▸ | CA2 | P00918 | 18/20 | 0.51 |
| ▸ | CA12 | O43570 | 18/20 | 0.51 |
| ▸ | CA9 | Q16790 | 18/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380601 | 0.88 | KMT2A (0.51) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL5383968 | 0.88 | KMT2A (0.44) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL5382246 | 0.87 | CA12 (0.43) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL5392664 | 0.87 | KMT2A (0.48) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL5385125 | 0.87 | PTGS2 (0.40) | CA1CA2CA12CA9 | |
| SCHEMBL5381880 | 0.86 | CA1 (0.64) | CA1CA2CA12CA9CA14 | |
| SCHEMBL5384224 | 0.86 | KMT2A (0.42) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL14505158 | 0.85 | CA1 (0.70) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL5382864 | 0.85 | MEN1 (0.47) | SMN1; SMN2 | |
| SCHEMBL5445970 | 0.85 | IDH2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | CA1 4865/4885CA2 4432/4885CA12 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.